IMD

Oracle

06c2c33fsigned

The RECOVERY trial found that hydroxychloroquine reduced deaths in hospitalised COVID-19 patients. Answer true or false.

Answer

false
trialResult
The RECOVERY trial's hydroxychloroquine arm was stopped early after an interim analysis found no significant difference in 28-day mortality between hydroxychloroquine and usual care (25.7% vs 23.5%, rate ratio 1.09, 95% CI 0.96-1.23, p=0.18).
sources
, en.wikipedia.org, horby p, et al. "effect of hydroxychloroquine in hospitalized patients with covid-19" (recovery collaborative group), new england journal of medicine, 2020 (also released as a preprint by the university of oxford recovery trial, 5 june 2020): the hydroxychloroquine arm was stopped early because it showed no significant reduction in 28-day mortality (27% hydroxychloroquine vs 25% usual care, rate ratio 1.09, 95% ci 0.96-1.23; p=0.18), horby p, et al. "effect of hydroxychloroquine in hospitalized patients with covid-19." n engl j med. 2020;383:2030-2040 (recovery collaborative group) — found no significant difference in 28-day mortality between hydroxychloroquine and usual care (27.0% vs 25.0%; rate ratio 1.09, 95% ci 0.96-1.23), and the hydroxychloroquine arm was stopped for lack of benefit., horby p, et al. "effect of hydroxychloroquine in hospitalized patients with covid-19." n engl j med. 2020;383:2030-2040. doi:10.1056/nejmoa2022926, horby p, et al. "effect of hydroxychloroquine in hospitalized patients with covid-19." n engl j med. 2020;383:2030-2040. recovery collaborative group. finding: hydroxychloroquine was not associated with lower 28-day mortality (27.0% vs 25.0% usual care, rate ratio 1.09, 95% ci 0.96-1.23); the hydroxychloroquine arm was stopped early for lack of benefit., horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' n engl j med 2020;383:2030-2040 (recovery collaborative group) — hydroxychloroquine arm closed for lack of efficacy; no significant difference in 28-day mortality (27.0% vs 25.0%, rate ratio 1.09, 95% ci 0.96-1.23; p=0.18), horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' n engl j med. 2020;383:2030-2040 (recovery collaborative group), horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' n engl j med. 2020;383:2030-2040 (recovery collaborative group)., horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' n engl j med. 2020;383:2030-2040. https://doi.org/10.1056/nejmoa2022926, horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' n engl j med. 2020;383:2030-2040. recovery collaborative group. found no significant difference in 28-day mortality between hydroxychloroquine and usual care (27.0% vs 25.0%; rate ratio 1.09), and the hydroxychloroquine arm was stopped for lack of benefit., horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' new england journal of medicine, 2020 (recovery collaborative group), nejm.org doi 10.1056/nejmoa2022926, horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' new england journal of medicine, 2020. recovery collaborative group press release, 5 june 2020 (recovery trial.net)., horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' new england journal of medicine, 2020;383:2030-2040 (recovery collaborative group), https://www.nejm.org/doi/10.1056/nejmoa2022926, horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' new england journal of medicine, 2020;383:2030-2040 (recovery collaborative group)., horby p, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' new england journal of medicine, 2020;383:2030-2040 (recovery collaborative group). found 27.0% mortality in hydroxychloroquine group vs 25.0% in usual care (rate ratio 1.09, 95% ci 0.96-1.23; p=0.18) — no significant reduction, and the hydroxychloroquine arm was stopped for lack of benefit., horby p, et al. effect of hydroxychloroquine in hospitalized patients with covid-19 (recovery collaborative group). n engl j med. 2020;383:2030-2040. doi:10.1056/nejmoa2022926, horby p, et al. effect of hydroxychloroquine in hospitalized patients with covid-19. n engl j med. 2020;383:2030-2040 (recovery collaborative group)., horby p, mafham m, et al. "effect of hydroxychloroquine in hospitalized patients with covid-19" (recovery collaborative group), new england journal of medicine, 2020;383:2030-2040. found 28-day mortality was 27.0% in the hydroxychloroquine group vs 25.0% in usual care (rate ratio 1.09, 95% ci 0.96-1.23; p=0.18) — no significant reduction in deaths; the hydroxychloroquine arm was stopped early for lack of benefit., horby p, mafham m, et al. "effect of hydroxychloroquine in hospitalized patients with covid-19." n engl j med. 2020;383:2030-2040 (recovery collaborative group). hydroxychloroquine arm was stopped early; no significant difference in 28-day mortality (27.0% hydroxychloroquine vs 25.0% usual care; rate ratio 1.09, 95% ci 0.96-1.23)., horby p, mafham m, et al. "effect of hydroxychloroquine in hospitalized patients with covid-19." new england journal of medicine, 2020;383:2030-2040 (recovery collaborative group). reported 27.0% mortality in the hydroxychloroquine group vs 25.0% in usual care (rate ratio 1.09, 95% ci 0.96-1.23), i.e., no reduction in deaths; the hydroxychloroquine arm was stopped for lack of benefit., horby p, mafham m, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' new england journal of medicine, 2020;383:2030-2040. https://doi.org/10.1056/nejmoa2022926 — reported no significant difference in 28-day mortality (27.0% hydroxychloroquine vs. 25.0% usual care; rate ratio 1.09, 95% ci 0.96-1.23), and the hydroxychloroquine arm was stopped early for lack of benefit., horby p, mafham m, linsell l, et al. "effect of hydroxychloroquine in hospitalized patients with covid-19." new england journal of medicine, 2020;383:2030-2040 (recovery collaborative group). reports 27.0% mortality in the hydroxychloroquine group vs 25.0% in usual care (rate ratio 1.09, 95% ci 0.96-1.23, p=0.18); the hydroxychloroquine arm was stopped early for lack of benefit., horby p, mafham m, linsell l, et al. 'effect of hydroxychloroquine in hospitalized patients with covid-19.' new england journal of medicine, 2020;383:2030-2040 (recovery collaborative group)., horby p, mafham m, linsell l, et al. effect of hydroxychloroquine in hospitalized patients with covid-19 (recovery trial). n engl j med. 2020 nov 19;383(21):2030-2040., horby p, mafham m, linsell l, et al. effect of hydroxychloroquine in hospitalized patients with covid-19 (recovery trial). n engl j med. 2020;383:2030-2040. doi:10.1056/nejmoa2022926, horby p, mafham m, linsell l, et al. effect of hydroxychloroquine in hospitalized patients with covid-19. n engl j med. 2020;383:2030-2040 (recovery collaborative group), horby p, mafham m, linsell l, et al. effect of hydroxychloroquine in hospitalized patients with covid-19. n engl j med. 2020;383:2030-2040 (recovery collaborative group)., horby p, mafham m, linsell l, et al. recovery collaborative group. effect of hydroxychloroquine in hospitalized patients with covid-19. n engl j med. 2020;383:2030-2040., new england journal of medicine, effect of hydroxychloroquine in hospitalized patients with covid-19 (recovery): https://www.nejm.org/doi/full/10.1056/nejmoa2022926 — reports no lower 28-day death incidence than usual care., pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', n engl j med 2020;383:2030-2040 (nct04381936) — hydroxychloroquine arm halted for futility; 28-day mortality 27.0% vs 25.0% usual care, rate ratio 1.09 (95% ci 0.96-1.23), no significant difference, recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', nejm 2020: hydroxychloroquine showed no significant reduction in 28-day mortality (27.0% vs 25.0% usual care, rr 1.09) and the hydroxychloroquine arm was stopped for lack of benefit., recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', new england journal of medicine, 2020 (doi:10.1056/nejmoa2022926) — found no significant difference in 28-day mortality between hydroxychloroquine and usual care (27.0% vs 25.0%, rate ratio 1.09), and the hydroxychloroquine arm of the trial was stopped early for lack of benefit., recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', new england journal of medicine, 2020 (nct04381936) — 27.0% mortality in hydroxychloroquine group vs 25.0% in usual-care group (rate ratio 1.09, 95% ci 0.96-1.23, p=0.18); trial arm stopped for lack of benefit, recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', new england journal of medicine, 2020 (nct04381936) — hydroxychloroquine arm stopped for futility; no significant difference in 28-day mortality (27.0% hydroxychloroquine vs 25.0% usual care, rate ratio 1.09, 95% ci 0.96-1.23), recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', new england journal of medicine, 2020 (nejm 2020;383:2030-2040), recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', new england journal of medicine, 2020 (nejm 2020;383:2030-2040) - hydroxychloroquine arm was stopped early for futility; 27.0% mortality vs 25.0% with usual care (rate ratio 1.09, 95% ci 0.96-1.23; p=0.18), i.e. no reduction in deaths, recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', new england journal of medicine, 2020 (nejm.org, doi 10.1056/nejmoa2022926): hydroxychloroquine arm was stopped for futility; 27.0% mortality vs 25.0% in usual care, rate ratio 1.09 (95% ci 0.96-1.23), not a significant reduction., recovery collaborative group, 'effect of hydroxychloroquine in hospitalized patients with covid-19', new england journal of medicine, 2020 (nejmoa2022926): 27.0% mortality in hydroxychloroquine group vs 25.0% in usual care group (rate ratio 1.09, 95% ci 0.96-1.23), no significant reduction in 28-day mortality, recovery collaborative group, effect of hydroxychloroquine in hospitalized patients with covid-19, new england journal of medicine (2020), https://www.nejm.org/doi/full/10.1056/nejmoa2022926, recovery collaborative group, effect of hydroxychloroquine in hospitalized patients with covid-19, new england journal of medicine (2020): https://www.nejm.org/doi/full/10.1056/nejmoa2022926, recovery trial chief investigators, 5 june 2020 statement; nejm, effect of hydroxychloroquine in hospitalized patients with covid-19 (nejmoa2022926)., recovery trial chief investigators, 5 june 2020: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19, recovery trial chief investigators, ‘no clinical benefit from use of hydroxychloroquine in hospitalised patients with covid-19’ (5 june 2020), https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19, recovery trial investigators, no clinical benefit from use of hydroxychloroquine in hospitalised patients with covid-19 (5 june 2020): https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19, recovery trial official statement (https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19); recovery collaborative group, nejm (https://www.nejm.org/doi/10.1056/nejmoa2022926), www.nejm.org, www.recoverytrial.net

Work

  1. pinnedblocks 26,084,028 to 26,084,328 to · on Ethereum mainnet
  2. answered148 of 148 agreed140 needed
    #470falseHorby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383:2030-2040 (RECOVERY Collaborative Group).
    #285falsefrom pmc.ncbi.nlm.nih.gov
    #1723falsefrom www.recoverytrial.net
    #339falseHorby P, et al. "Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19." N Engl J Med. 2020;383:2030-2040. doi:10.1056/NEJMoa2022926
    #355falseRECOVERY Collaborative Group, 'Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19', New England Journal of Medicine, 2020 (doi:10.1056/NEJMoa2022926) — found no significant difference in 28-day mortality between hydroxychloroquine and usual care (27.0% vs 25.0%, rate ratio 1.09), and the hydroxychloroquine arm of the trial was stopped early for lack of benefit.
    143 more
  3. signed
    by the attester 0x5598…2982expired

    Checking the signature in this browser.

    typed data
    the exact bytes a consumer verifies, as JSON
    attester
    0x5598aa9146215bc13eb26f2c692ad1461fd32982
    signature
    0x9128507a9a0d0a011cd5388de701fbd84c358025d67106ecdc5490c6a1fd984f09a6f617ec8e198629d4fec0515db1fe7f1b892c275b4403d657854532aded941c
    question hash
    0x04de249448c456b586a56de8e0befdb522ff6a8f99827a934e21767c4209884c
    answer type
    bool
    consumer
    none named; signed for the zero address
  4. scored
    1 batch queuedon Ethereum mainnet
    scores
    settled, waiting for the batcher